The DOI matches its Crossref record; 146 of the 146 references it cites were found in a registry or an index.
Cancer of the ovary, fallopian tube, and peritoneum: 2021 update
Open accessAbstract
In 2014, FIGO’s Committee for Gynecologic Oncology revised the staging of ovarian cancer, incorporating ovarian, fallopian tube, and peritoneal cancer into the same system. Most of these malignancies are high‐grade serous carcinomas (HGSC). Stage IC is now divided into three categories: IC1 (surgical spill); IC2 (capsule ruptured before surgery or tumor on ovarian or fallopian tube surface); and IC3 (malignant cells in the ascites or peritoneal washings). The updated staging includes a revision of Stage IIIC based on spread to the retroperitoneal lymph nodes alone without intraperitoneal dissemination. This category is now subdivided into IIIA1(i) (metastasis ≤10 mm in greatest dimension), and IIIA1(ii) (metastasis >10 mm in greatest dimension). Stage IIIA2 is now “microscopic extrapelvic peritoneal involvement with or without positive retroperitoneal lymph node” metastasis. This review summarizes the genetics, surgical management, chemotherapy, and targeted therapies for epithelial cancers, and the treatment of ovarian germ cell and stromal malignancies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Siegel, R. L., Miller, K. D., & Jemal, A. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21590 · Cited by 20,444
Amin, M. B., Greene, F. L., Edge, S. B., Compton, C. C., Gershenwald, J. E., Brookland, R. K., Meyer, L., Gress, D. M., Byrd, D. R., & Winchester, D. P. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21388 · Cited by 6,502
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Moore, K., Colombo, N., Scambia, G., Kim, B.-G., Oaknin, A., Friedlander, M., Lisyanskaya, A., Floquet, A., Leary, A., Sonke, G. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810858 · Cited by 2,870
Self-citationIntraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Armstrong, D. K., Bundy, B., Wenzel, L., Huang, H. Q., Baergen, R., Lele, S., Copeland, L. J., Walker, J. L., & Burger, R. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052985 · Cited by 2,625
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
Vergote, I., Tropé, C. G., Amant, F., Kristensen, G. B., Ehlen, T., Johnson, N., Verheijen, R. H. M., van der Burg, M. E. L., Lacave, A. J., Panici, P. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908806 · Cited by 2,537
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
Mirza, M. R., Monk, B. J., Herrstedt, J., Oza, A. M., Mahner, S., Redondo, A., Fabbro, M., Ledermann, J. A., Lorusso, D., Vergote, I., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611310 · Cited by 2,451
Self-citationIncorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Burger, R. A., Brady, M. F., Bookman, M. A., Fleming, G. F., Monk, B. J., Huang, H., Mannel, R. S., Homesley, H. D., Fowler, J., Greer, B. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104390 · Cited by 2,404
Bristow, R. E., Tomacruz, R. S., Armstrong, D. K., Trimble, E. L., & Montz, F. J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.5.1248 · Cited by 2,312
The Risk of Cancer Associated with Specific Mutations of BRCA1 and BRCA2 among Ashkenazi Jews
Struewing, J. P., Hartge, P., Wacholder, S., Baker, S. M., Berlin, M., McAdams, M., Timmerman, M. M., Brody, L. C., & Tucker, M. A. (1997) · New England Journal of Medicine · doi:10.1056/nejm199705153362001 · Cited by 2,281
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
González-Martín, A., Pothuri, B., Vergote, I., DePont Christensen, R., Graybill, W., Mirza, M. R., McCormick, C., Lorusso, D., Hoskins, P., Freyer, G., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910962 · Cited by 2,263
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
Perren, T. J., Swart, A. M., Pfisterer, J., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G., Carey, M. S., Beale, P., Cervantes, A., Kurzeder, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103799 · Cited by 2,172
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
Ray-Coquard, I., Pautier, P., Pignata, S., Pérol, D., González-Martín, A., Berger, R., Fujiwara, K., Vergote, I., Colombo, N., Mäenpää, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911361 · Cited by 2,055
Ozols, R. F., Bundy, B. N., Greer, B. E., Fowler, J. M., Clarke-Pearson, D., Burger, R. A., Mannel, R. S., DeGeest, K., Hartenbach, E. M., & Baergen, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.153 · Cited by 2,032
WHO classification of tumours of female reproductive organs
Kurman, R. J., Carcangiu, M. L., Herrington, C. S., & Young, R. H. (2014) · International Agency for Research on Cancer eBooks · Cited by 1,966
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., Scott, C., Meier, W., Shapira-Frommer, R., Safra, T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105535 · Cited by 1,883
Self-citationCarboplatin dosage: prospective evaluation of a simple formula based on renal function.
Calvert, A. H., Newell, D. R., Gumbrell, L. A., O'Reilly, S., Burnell, M., Boxall, F. E., Siddik, Z. H., Judson, I. R., Gore, M. E., & Wiltshaw, E. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.11.1748 · Cited by 1,866
Pujade-Lauraine, E., Ledermann, J. A., Selle, F., Gebski, V., Penson, R. T., Oza, A. M., Korach, J., Huzarski, T., Poveda, A., Pignata, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30469-2 · Cited by 1,855
Self-citationColeman, R. L., Oza, A. M., Lorusso, D., Aghajanian, C., Oaknin, A., Dean, A., Colombo, N., Weberpals, J. I., Clamp, A., Scambia, G., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32440-6 · Cited by 1,693
Self-citationOlaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
Kaufman, B., Shapira-Frommer, R., Schmutzler, R. K., Audeh, M. W., Friedlander, M., Balmaña, J., Mitchell, G., Fried, G., Stemmer, S. M., Hubert, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2728 · Cited by 1,671
Self-citationPujade-Lauraine, E., Hilpert, F., Weber, B., Reuss, A., Poveda, A., Kristensen, G., Sorio, R., Vergote, I., Witteveen, P., Bamias, A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.4489 · Cited by 1,622
Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., Scott, C. L., Meier, W., Shapira-Frommer, R., Safra, T., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70228-1 · Cited by 1,442
Self-citationHyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
van Driel, W. J., Koole, S. N., Sikorska, K., Schagen van Leeuwen, J. H., Schreuder, H. W. R., Hermans, R. H. M., de Hingh, I. H. J. T., van der Velden, J., Arts, H. J., Massuger, L. F. A. G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1708618 · Cited by 1,426
Kehoe, S., Hook, J., Nankivell, M., Jayson, G. C., Kitchener, H., Lopes, T., Luesley, D., Perren, T., Bannoo, S., Mascarenhas, M., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62223-6 · Cited by 1,414
Self-citationAghajanian, C., Blank, S. V., Goff, B. A., Judson, P. L., Teneriello, M. G., Husain, A., Sovak, M. A., Yi, J., & Nycum, L. R. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.0505 · Cited by 1,384
Staging classification for cancer of the ovary, fallopian tube, and peritoneum
Prat, J. (2014) · International Journal of Gynecology & Obstetrics · doi:10.1016/j.ijgo.2013.10.001 · Cited by 1,364
Buys, S. S. (2011) · JAMA · doi:10.1001/jama.2011.766 · Cited by 1,323
Alberts, D. S., Liu, P. Y., Hannigan, E. V., O'Toole, R., Williams, S. D., Young, J. A., Franklin, E. W., Clarke-Pearson, D. L., Malviya, V. K., DuBeshter, B., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199612263352603 · Cited by 1,228
Gordon, A. N., Fleagle, J. T., Guthrie, D., Parkin, D. E., Gore, M. E., & Lacave, A. J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.14.3312 · Cited by 1,211
Swisher, E. M., Lin, K. K., Oza, A. M., Scott, C. L., Giordano, H., Sun, J., Konecny, G. E., Coleman, R. L., Tinker, A. V., O'Malley, D. M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30559-9 · Cited by 1,196
Kindelberger, D. W., Lee, Y., Miron, A., Hirsch, M. S., Feltmate, C., Medeiros, F., Callahan, M. J., Garner, E. O., Gordon, R. W., Birch, C., et al. (2007) · The American Journal of Surgical Pathology · doi:10.1097/01.pas.0000213335.40358.47 · Cited by 1,113
Markman, M., Bundy, B. N., Alberts, D. S., Fowler, J. M., Clark-Pearson, D. L., Carson, L. F., Wadler, S., & Sickel, J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.4.1001 · Cited by 1,080
Jacobs, I. J., Menon, U., Ryan, A., Gentry-Maharaj, A., Burnell, M., Kalsi, J. K., Amso, N. N., Apostolidou, S., Benjamin, E., Cruickshank, D., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01224-6 · Cited by 1,048
Walsh, T., Casadei, S., Lee, M. K., Pennil, C. C., Nord, A. S., Thornton, A. M., Roeb, W., Agnew, K. J., Stray, S. M., Wickramanayake, A., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1115052108 · Cited by 933
Medeiros, F., Muto, M. G., Lee, Y., Elvin, J. A., Callahan, M. J., Feltmate, C., Garber, J. E., Cramer, D. W., & Crum, C. P. (2006) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000180854.28831.77 · Cited by 916
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer
Coleman, R. L., Fleming, G. F., Brady, M. F., Swisher, E. M., Steffensen, K. D., Friedlander, M., Okamoto, A., Moore, K. N., Efrat Ben-Baruch, N., Werner, T. L., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1909707 · Cited by 913
Self-citationOza, A. M., Cook, A. D., Pfisterer, J., Embleton, A., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G., Carey, M. S., Beale, P., Cervantes, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00086-8 · Cited by 875
Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.
Markman, M., Rothman, R., Hakes, T., Reichman, B., Hoskins, W., Rubin, S., Jones, W., Almadrones, L., & Lewis, J. L. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.3.389 · Cited by 839
Inherited Mutations in Women With Ovarian Carcinoma
Norquist, B. M., Harrell, M. I., Brady, M. F., Walsh, T., Lee, M. K., Gulsuner, S., Bernards, S. S., Casadei, S., Yi, Q., Burger, R. A., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.5495 · Cited by 769
Pfisterer, J., Plante, M., Vergote, I., du Bois, A., Hirte, H., Lacave, A. J., Wagner, U., Stähle, A., Stuart, G., Kimmig, R., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.0913 · Cited by 754
Katsumata, N., Yasuda, M., Takahashi, F., Isonishi, S., Jobo, T., Aoki, D., Tsuda, H., Sugiyama, T., Kodama, S., Kimura, E., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61157-0 · Cited by 727
Bookman, M. A., Brady, M. F., McGuire, W. P., Harper, P. G., Alberts, D. S., Friedlander, M., Colombo, N., Fowler, J. M., Argenta, P. A., De Geest, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.1684 · Cited by 705
Self-citationvan der Burg, M. E. L., van Lent, M., Buyse, M., Kobierska, A., Colombo, N., Favalli, G., Lacave, A. J., Nardi, M., Renard, J., & Pecorelli, S. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503093321002 · Cited by 705
Risch, H. A., McLaughlin, J. R., Cole, D. E. C., Rosen, B., Bradley, L., Fan, I., Tang, J., Li, S., Zhang, S., Shaw, P. A., et al. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj465 · Cited by 680
Trimbos, J. B., Vergote, I., Bolis, G., Vermorken, J. B., Mangioni, C., Madronal, C., Franchi, M., Tateo, S., Zanetta, G., Scarfone, G., et al. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.2.113 · Cited by 674
Granulosa Cell Tumor of the Ovary
Schumer, S. T., & Cannistra, S. A. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.019 · Cited by 674
Vasey, P. A., Jayson, G. C., Gordon, A., Gabra, H., Coleman, R., Atkinson, R., Parkin, D., Paul, J., Hay, A., Kaye, S. B., et al. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh323 · Cited by 632
Tumors of the Ovary, Maldeveloped Gonads, Fallopian Tube, and Broad Ligament
Scully, R. E., Young, R. H., & Clement, P. B. (1999) · International Journal of Gynecological Pathology · doi:10.1097/00004347-199907000-00019 · Cited by 617
Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial
Rustin, G. J., van der Burg, M. E., Griffin, C. L., Guthrie, D., Lamont, A., Jayson, G. C., Kristensen, G., Mediola, C., Coens, C., Qian, W., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61268-8 · Cited by 599
A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms
Harter, P., Sehouli, J., Lorusso, D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1808424 · Cited by 594
Young, R. C., Walton, L. A., Ellenberg, S. S., Homesley, H. D., Wilbanks, G. D., Decker, D. G., Miller, A., Park, R., & Major, F. (1990) · New England Journal of Medicine · doi:10.1056/nejm199004123221501 · Cited by 583
van der Burg, M. E. L., van Lent, M., Buyse, M., Kobierska, A., Colombo, N., Favalli, G., Lacave, A. J., Nardi, M., Renard, J., & Pecorelli, S. (1995) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-199507000-00012 · Cited by 578
Konstantinopoulos, P. A., Waggoner, S., Vidal, G. A., Mita, M., Moroney, J. W., Holloway, R., Van Le, L., Sachdev, J. C., Chapman-Davis, E., Colon-Otero, G., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.1048 · Cited by 563
The distal fallopian tube: a new model for pelvic serous carcinogenesis
Crum, C. P., Drapkin, R., Miron, A., Ince, T. A., Muto, M., Kindelberger, D. W., & Lee, Y. (2007) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0b013e328011a21f · Cited by 512
Callahan, M. J., Crum, C. P., Medeiros, F., Kindelberger, D. W., Elvin, J. A., Garber, J. E., Feltmate, C. M., Berkowitz, R. S., & Muto, M. G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.2622 · Cited by 485
Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer
Tewari, K. S., Burger, R. A., Enserro, D., Norquist, B. M., Swisher, E. M., Brady, M. F., Bookman, M. A., Fleming, G. F., Huang, H., Homesley, H. D., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01009 · Cited by 483
Katsumata, N., Yasuda, M., Isonishi, S., Takahashi, F., Michimae, H., Kimura, E., Aoki, D., Jobo, T., Kodama, S., Terauchi, F., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70363-2 · Cited by 480
Kurman, R. J., & Shih, I.-M. (2008) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0b013e318161e4f5 · Cited by 460
Fagotti, A., Ferrandina, M. G., Vizzielli, G., Pasciuto, T., Fanfani, F., Gallotta, V., Margariti, P. A., Chiantera, V., Costantini, B., Gueli Alletti, S., et al. (2020) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2020-001640 · Cited by 451
Primary cytoreductive surgery for epithelial ovarian cancer.
Hacker, N. F., Berek, J. S., Lagasse, L. D., Nieberg, R. K., & Elashoff, R. M. (1983) · PubMed · Cited by 437
Self-citationDisis, M. L., Taylor, M. H., Kelly, K., Beck, J. T., Gordon, M., Moore, K. M., Patel, M. R., Chaves, J., Park, H., Mita, A. C., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.6258 · Cited by 437
Zanetta, G., Rota, S., Chiari, S., Bonazzi, C., Bratina, G., & Mangioni, C. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.10.2658 · Cited by 420
Farley, J., Brady, W. E., Vathipadiekal, V., Lankes, H. A., Coleman, R., Morgan, M. A., Mannel, R., Yamada, S. D., Mutch, D., Rodgers, W. H., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70572-7 · Cited by 413
New Insights Into the Pathogenesis of Serous Ovarian Cancer and Its Clinical Impact
Levanon, K., Crum, C., & Drapkin, R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1107 · Cited by 412
Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer
Monk, B. J., Herzog, T. J., Kaye, S. B., Krasner, C. N., Vermorken, J. B., Muggia, F. M., Pujade-Lauraine, E., Lisyanskaya, A. S., Makhson, A. N., Rolski, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.4037 · Cited by 395
Pignata, S., Scambia, G., Katsaros, D., Gallo, C., Pujade-Lauraine, E., De Placido, S., Bologna, A., Weber, B., Raspagliesi, F., Panici, P. B., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70049-x · Cited by 389
Ray-Coquard, I., Morice, P., Lorusso, D., Prat, J., Oaknin, A., Pautier, P., & Colombo, N. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy001 · Cited by 374
Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer
Jaaback, K., Johnson, N., & Lawrie, T. A. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005340.pub4 · Cited by 359
Chi, D. S., McCaughty, K., Diaz, J. P., Huh, J., Schwabenbauer, S., Hummer, A. J., Venkatraman, E. S., Aghajanian, C., Sonoda, Y., Abu‐Rustum, N. R., et al. (2006) · Cancer · doi:10.1002/cncr.21845 · Cited by 350
Carlson, J. W., Miron, A., Jarboe, E. A., Parast, M. M., Hirsch, M. S., Lee, Y., Muto, M. G., Kindelberger, D., & Crum, C. P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.4814 · Cited by 347
Zamarin, D., Burger, R. A., Sill, M. W., Powell, D. J., Lankes, H. A., Feldman, M. D., Zivanovic, O., Gunderson, C., Ko, E., Mathews, C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02059 · Cited by 345
Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer
Coleman, R. L., Spirtos, N. M., Enserro, D., Herzog, T. J., Sabbatini, P., Armstrong, D. K., Kim, J.-W., Park, S.-Y., Kim, B.-G., Nam, J.-H., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1902626 · Cited by 338
Cancer of the ovary, fallopian tube, and peritoneum
Berek, J. S., Kehoe, S. T., Kumar, L., & Friedlander, M. (2018) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.12614 · Cited by 327
Self-citationManagement of Ovarian Stromal Cell Tumors
Colombo, N., Parma, G., Zanagnolo, V., & Insinga, A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.1005 · Cited by 326
Chetrit, A., Hirsh-Yechezkel, G., Ben-David, Y., Lubin, F., Friedman, E., & Sadetzki, S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.6905 · Cited by 323
Inhibin as a Marker for Granulosa-Cell Tumors
Lappöhn, R. E., Burger, H. G., Bouma, J., Bangah, M., Krans, M., & De Bruijn, H. W. A. (1989) · New England Journal of Medicine · doi:10.1056/nejm198909213211204 · Cited by 323
Cancer of the ovary, fallopian tube, and peritoneum
Berek, J. S., Crum, C., & Friedlander, M. (2012) · International Journal of Gynecology & Obstetrics · doi:10.1016/s0020-7292(12)60025-3 · Cited by 322
Self-citationBell, J., Brady, M. F., Young, R. C., Lage, J., Walker, J. L., Look, K. Y., Rose, G. S., & Spirtos, N. M. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.06.013 · Cited by 307
Vergote, I., Coens, C., Nankivell, M., Kristensen, G. B., Parmar, M. K. B., Ehlen, T., Jayson, G. C., Johnson, N., Swart, A. M., Verheijen, R., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30566-7 · Cited by 306
Self-citationBöhm, S., Faruqi, A., Said, I., Lockley, M., Brockbank, E., Jeyarajah, A., Fitzpatrick, A., Ennis, D., Dowe, T., Santos, J. L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.5212 · Cited by 303
Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant
Gershenson, D. M., Sun, C. C., Bodurka, D., Coleman, R. L., Lu, K. H., Sood, A. K., Deavers, M., Malpica, A. L., & Kavanagh, J. J. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.03.001 · Cited by 291
Clinical Behavior of Stage II-IV Low-Grade Serous Carcinoma of the Ovary
Gershenson, D. M., Sun, C. C., Lu, K. H., Coleman, R. L., Sood, A. K., Malpica, A., Deavers, M. T., Silva, E. G., & Bodurka, D. C. (2006) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000227787.24587.d1 · Cited by 290
Colombo, N., Peiretti, M., Garbi, A., Carinelli, S., Marini, C., & Sessa, C. (2012) · Annals of Oncology · doi:10.1093/annonc/mds223 · Cited by 290
Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer
Burghardt, E., Girardi, F., Lahousen, M., Tamussino, K., & Stettner, H. (1991) · Gynecologic Oncology · doi:10.1016/0090-8258(91)90099-q · Cited by 285
Screening for Ovarian Cancer: US Preventive Services Task Force Recommendation Statement
US Preventive Services Task Force, Grossman, D. C., Curry, S. J., Owens, D. K., Barry, M. J., Davidson, K. W., Doubeni, C. A., Epling, J. W., Kemper, A. R., Krist, A. H., et al. (2018) · JAMA · doi:10.1001/jama.2017.21926 · Cited by 283
Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum
Gershenson, D. M., Bodurka, D. C., Coleman, R. L., Lu, K. H., Malpica, A., & Sun, C. C. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.0632 · Cited by 279
Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma
Soslow, R. A., Han, G., Park, K. J., Garg, K., Olvera, N., Spriggs, D. R., Kauff, N. D., & Levine, D. A. (2012) · Modern Pathology · doi:10.1038/modpathol.2011.183 · Cited by 262
Shapiro, J. D., Millward, M. J., Rischin, D., Michael, M., Walcher, V., Francis, P. A., & Toner, G. C. (1996) · Gynecologic Oncology · doi:10.1006/gyno.1996.0284 · Cited by 250
Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum
Schmeler, K. M., Sun, C. C., Bodurka, D. C., T. Deavers, M., Malpica, A., Coleman, R. L., Ramirez, P. T., & Gershenson, D. M. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.11.013 · Cited by 245
Advanced Ovarian Cancer Trialists' Group, Aabo, K., Adams, M., Adnitt, P., Alberts, D., Athanazziou, A., Barley, V, Bell, D., Bianchi, U., Bolis, G., et al. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.710 · Cited by 234
Grabowski, J. P., Harter, P., Heitz, F., Pujade-Lauraine, E., Reuss, A., Kristensen, G., Ray-Coquard, I., Heitz, J., Traut, A., Pfisterer, J., et al. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.01.022 · Cited by 233
Poveda, A. M., Selle, F., Hilpert, F., Reuss, A., Savarese, A., Vergote, I., Witteveen, P., Bamias, A., Scotto, N., Mitchell, L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.1408 · Cited by 232
Walker, J. L., Brady, M. F., Wenzel, L., Fleming, G. F., Huang, H. Q., DiSilvestro, P. A., Fujiwara, K., Alberts, D. S., Zheng, W., Tewari, K. S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01568 · Cited by 231
Pignata, S., Scambia, G., Ferrandina, G., Savarese, A., Sorio, R., Breda, E., Gebbia, V., Musso, P., Frigerio, L., Del Medico, P., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.8566 · Cited by 229
Clinical Trials in Recurrent Ovarian Cancer
Friedlander, M., Trimble, E., Tinker, A., Alberts, D., Avall-Lundqvist, E., Brady, M., Harter, P., Pignata, S., Pujade-Lauraine, E., Sehouli, J., et al. (2011) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e31821bb8aa · Cited by 224
Self-citationA Genetic Epidemiological Study of Carcinoma of the Fallopian Tube
Aziz, S., Kuperstein, G., Rosen, B., Cole, D., Nedelcu, R., McLaughlin, J., & Narod, S. A. (2001) · Gynecologic Oncology · doi:10.1006/gyno.2000.6095 · Cited by 222
BRAF Mutation Is Rare in Advanced-Stage Low-Grade Ovarian Serous Carcinomas
Wong, K.-K., Tsang, Y. T. M., Deavers, M. T., Mok, S. C., Zu, Z., Sun, C., Malpica, A., Wolf, J. K., Lu, K. H., & Gershenson, D. M. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.100212 · Cited by 220
Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum
Gershenson, D. M., Sun, C. C., Iyer, R. B., Malpica, A. L., Kavanagh, J. J., Bodurka, D. C., Schmeler, K., & Deavers, M. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.02.037 · Cited by 210
Lheureux, S., Cristea, M. C., Bruce, J. P., Garg, S., Cabanero, M., Mantia-Smaldone, G., Olawaiye, A. B., Ellard, S. L., Weberpals, J. I., Wahner Hendrickson, A. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32554-x · Cited by 210
Rosenthal, A. N., Fraser, L. S. M., Philpott, S., Manchanda, R., Burnell, M., Badman, P., Hadwin, R., Rizzuto, I., Benjamin, E., Singh, N., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.9330 · Cited by 209
Clamp, A. R., James, E. C., McNeish, I. A., Dean, A., Kim, J.-W., O'Donnell, D. M., Hook, J., Coyle, C., Blagden, S., Brenton, J. D., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32259-7 · Cited by 209
Wagner, U., Marth, C., Largillier, R., Kaern, J., Brown, C., Heywood, M., Bonaventura, T., Vergote, I., Piccirillo, M. C., Fossati, R., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.307 · Cited by 189
Miller, D. S., Blessing, J. A., Krasner, C. N., Mannel, R. S., Hanjani, P., Pearl, M. L., Waggoner, S. E., & Boardman, C. H. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.2963 · Cited by 186
Kennedy, A. W., & Hart, W. R. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960715)78:2<278::aid-cncr14>3.0.co;2-t · Cited by 175
Negri, E., Franceschi, S., Tzonou, A., Booth, M., La Vecchia, C., Parazzini, F., Beral, V., Boyle, P., & Trichopoulos, D. (1991) · International Journal of Cancer · doi:10.1002/ijc.2910490110 · Cited by 167
Oral etoposide is active against platinum-resistant epithelial ovarian cancer.
Hoskins, P. J., & Swenerton, K. D. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.1.60 · Cited by 166
Pfisterer, J., Shannon, C. M., Baumann, K., Rau, J., Harter, P., Joly, F., Sehouli, J., Canzler, U., Schmalfeldt, B., Dean, A. P., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30142-x · Cited by 166
(2019) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000003164 · Cited by 165
Symptoms associated with diagnosis of ovarian cancer: a systematic review
Bankhead, C. R., Kehoe, S. T., & Austoker, J. (2005) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2005.00572.x · Cited by 161
Self-citationReclassification of serous ovarian carcinoma by a 2‐tier system: A Gynecologic Oncology Group Study
Bodurka, D. C., Deavers, M. T., Tian, C., Sun, C. C., Malpica, A., Coleman, R. L., Lu, K. H., Sood, A. K., Birrer, M. J., Ozols, R., et al. (2012) · Cancer · doi:10.1002/cncr.26618 · Cited by 160
O’Malley, D. M., Matulonis, U. A., Birrer, M. J., Castro, C. M., Gilbert, L., Vergote, I. B., Martin, L. P., Mantia-Smaldone, G. M., González-Martín, A., Bratos, R., et al. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.01.037 · Cited by 159
Monk, B. J., Grisham, R. N., Banerjee, S. N., Kalbacher, E., Mirza, M. R., Romero, I., Vuylsteke, P., Coleman, R. L., Hilpert, F., Oza, A. M., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01164 · Cited by 158
Hermsen, B. B. J., Olivier, R. I., Verheijen, R. H. M., van Beurden, M., de Hullu, J. A., Massuger, L. F. A. G., Burger, C. W., Brekelmans, C. T. M., Mourits, M. J. E., de Bock, G. H., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603725 · Cited by 155
Gilbert, L., Basso, O., Sampalis, J. S., Karp, I., Martins, C., Feng, J., Piedimonte, S., Quintal, L., Ramanakumar, A. V., TAKEFMAN, J. E., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70333-3 · Cited by 155
McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E., Look, K. Y., Clarke‐Pearson, D. L., & Davidson, M. (1996) · PubMed · Cited by 150
Chan, J. K., Tian, C., Fleming, G. F., Monk, B. J., Herzog, T. J., Kapp, D. S., & Bell, J. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.10.073 · Cited by 148
Characterization of Active Mitogen-Activated Protein Kinase in Ovarian Serous Carcinomas
Hsu, C., Bristow, R. E., Cha, M. S., Wang, B. G., Ho, C., Kurman, R. J., Wang, T., & Shih, I. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0893 · Cited by 148
High-grade fimbrial-ovarian carcinomas are unified by altered p53, PTEN and PAX2 expression
Roh, M. H., Yassin, Y., Miron, A., Mehra, K. K., Mehrad, M., Monte, N. M., Mutter, G. L., Nucci, M. R., Ning, G., McKeon, F., et al. (2010) · Modern Pathology · doi:10.1038/modpathol.2010.119 · Cited by 137
Woodward, E. R., Sleightholme, H., Considine, A., Williamson, S., McHugo, J. M., & Crüger, D. G. (2007) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2007.01499.x · Cited by 137
Friedlander, M. L., Millward, M., Bell, D., Bugat, R., Harnett, P. R., Moreno, J. A., Campbell, L., Varette, C., Ripoche, V., & Kayitalire, L. (1998) · Annals of Oncology · doi:10.1023/a:1008469212268 · Cited by 137
Self-citationCurrent Update on Borderline Ovarian Neoplasms
Lalwani, N., Shanbhogue, K., Vikram, R., Nagar, A. M., Jagirdar, J. S., & Prasad, S. R. (2010) · American Journal of Roentgenology · doi:10.2214/ajr.09.3936 · Cited by 130
Testicular germ cell tumors: pathogenesis, diagnosis and treatment
Winter, C., & Albers, P. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.196 · Cited by 125
Secondary cytoreductive surgery for recurrent epithelial ovarian cancer
Tay, E. H. (2002) · Obstetrics and Gynecology · doi:10.1016/s0029-7844(02)01977-4 · Cited by 124
Incidental Nonuterine High-grade Serous Carcinomas Arise in the Fallopian Tube in Most Cases
Gilks, C. B., Irving, J., Köbel, M., Lee, C., Singh, N., Wilkinson, N. S., & McCluggage, W. G. (2014) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000353 · Cited by 123
Colombo, N., Kutarska, E., Dimopoulos, M. A., Bae, D., Rzepka-Górska, I., Bidziński, M., Scambia, G., Engelholm, S. A., Joly, F., Weber, D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.8082 · Cited by 122
Management of Platinum-Sensitive Recurrent Ovarian Cancer
Pfisterer, J., & Ledermann, J. A. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.03.012 · Cited by 121
Tamoxifen for relapse of ovarian cancer
Williams, C., Simera, I., & Bryant, A. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001034.pub2 · Cited by 108
Calculator for ovarian carcinoma subtype prediction
Kalloger, S. E., Köbel, M., Leung, S. C. Y., Mehl, E., Gao, D., Marcon, K. M., Chow, C., Clarke, B. A., Huntsman, D. D., & Gilks, C. B. (2010) · Modern Pathology · doi:10.1038/modpathol.2010.215 · Cited by 102
Fader, A. N., Bergstrom, J., Jernigan, A. M., Tanner, E. J., Roche, K. L., Stone, R. L., Levinson, K. L., Ricci, S., Wethingon, S., Wang, T., et al. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.07.127 · Cited by 102
Hurteau, J. A., Blessing, J. A., Decesare, S. L., & Creasman, W. T. (2001) · Gynecologic Oncology · doi:10.1006/gyno.2001.6255 · Cited by 100
Maintenance chemotherapy for ovarian cancer
Mei, L., Chen, H., Wei, D. M., Fang, F., Liu, G. J., Xie, H. Y., Wang, X., Zhou, J., & Feng, D. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007414.pub3 · Cited by 95
Geerts, I. S., Vergote, I., Neven, P., & Billen, J. (2009) · International Journal of Gynecological Cancer · doi:10.1111/igc.0b013e3181a702d1 · Cited by 95
Ayhan, A., Kurman, R. J., Yemelyanova, A. V., VANG, R. S., Logani, S., Seidman, J. D., & Shih, I. (2009) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181a24354 · Cited by 92
Survival differences of Asian and Caucasian epithelial ovarian cancer patients in the United States
Fuh, K. C., Shin, J. Y., Kapp, D. S., Brooks, R. A., Ueda, S. M., Urban, R. R., Chen, L.-M., & Chan, J. K. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.10.009 · Cited by 78
Lwin, Z., Gomez‐Roca, C., Saâda-Bouzid, E., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.2271 · Cited by 75
Chemotherapy for Advanced Germ Cell Tumors
Kondagunta, G. V., & Motzer, R. J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.7882 · Cited by 72
Vasey, P. A., Paul, J., Birt, A., Junor, E., Reed, N. S., Symonds, R. P., Rj, A., Graham, J., Crawford, S. M., Coleman, R. E., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.7.2069 · Cited by 71
Gershenson, D. M., Miller, A., Brady, W. E., Paul, J., Carty, K., Rodgers, W. H., Millan, D. W. M., Coleman, R. L., Moore, K. N., Banerjee, S. N., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz394.058 · Cited by 66
Hereditary ovarian cancer: Heterogeneity in age at onset
Lynch, H. T., Watson, P. A., Lynch, J. F., Conway, T., & Fili, M. (2010) · Cancer · doi:10.1002/cncr.2820710213 · Cited by 58
Ledermann, J. A., Colombo, N., Oza, A. M., Fujiwara, K., Birrer, M. J., Randall, L. M., Poddubskaya, E. V., Scambia, G., Shparyk, Y. V., Lim, M.-C., et al. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.06.025 · Cited by 56
Coghlan, E., Meniawy, T. M., Munro, A., Bulsara, M. K., Stewart, C. J. R., Tan, A. L. Y., Koay, M. H. E., MaGee, D., Codde, J., Tan, J., et al. (2017) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000000945 · Cited by 50
Maintenance chemotherapy for ovarian cancer
Mei, L., Chen, H., Wei, D. M., Fang, F., Liu, G. J., Xie, H. Y., Wang, X., Zou, J., Han, X., & Feng, D. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007414.pub2 · Cited by 34
Falandry, C., Savoye, A.-M., Stefani, L., Tinquaut, F., Lorusso, D., Herrstedt, J., Bourbouloux, E., Floquet, A., Brachet, P. E., Zannetti, A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.5508 · Cited by 32
Kok, P., Beale, P., O’Connell, R. L., Grant, P., Bonaventura, T., Scurry, J., Antill, Y. C., Goh, J. C. H., Sjoquist, K. M., DeFazio, A., et al. (2019) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2019.30.e86 · Cited by 28
Self-citationTargeted therapy for gynecologic cancers: Toward the era of precision medicine
Basu, P. S., Mukhopadhyay, A., & Konishi, I. (2018) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.12620 · Cited by 23
Cited by
Caruso, G., Weroha, S. J., & Cliby, W. (2025) · JAMA · doi:10.1001/jama.2025.9495 · Cited by 304
Deciphering the ghost proteome in ovarian cancer cells by deep proteogenomic characterization
Garcia-del Rio, D. F., Derhourhi, M., Bonnefond, A., Leblanc, S., Guilloy, N., Roucou, X., Eyckerman, S., Gevaert, K., Salzet, M., & Cardon, T. (2024) · Cell Death & Disease · doi:10.1038/s41419-024-07046-1 · Cited by 7
Metadata
- Authors
- Berek, J. S., Renz, M., Kehoe, S., Kumar, L., & Friedlander, M.
- Venue
- International Journal of Gynecology & Obstetrics
- Publisher
- Wiley
- Published
- 2021-10
- Volume
- 155
- Issue
- S1
- Pages
- 61-85
- ISSN
- 0020-6695 (ISSN-L)
- 0020-7292
- 1879-3479
- OpenAlex
- W3207350175
- Cited by
- 514
- References
- 146
- FWCI
- 50.71
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.